NY-NFL/OVERTIER
The National Football League (NFL) and OverTier, a Bruin Sports Capital (Bruin) company, today announced an expansion of their partnership for OverTier to operate NFL Game Pass, the league’s premium subscription OTT service. Since 2017, OverTier held the rights to operate NFL Game Pass in Europe. The new agreement now brings the service to a combined 181 countries and territories worldwide including Australia, Brazil, Hong Kong, India, Israel, Japan, Mexico, and South Korea.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191007005597/en/
NFL Game Pass offers all live NFL Games, NFL Red Zone, NFL Network and a deep catalog of original programming, documentaries, series and specials from the award-winning NFL Films. It is available across 11 platforms through connected TV, games consoles, web and mobile.
“We are excited to expand our partnership with OverTier to bring the NFL directly to fans around the world on their favorite viewing platforms with NFL Game Pass,” said Chris Halpin, NFL Chief Strategy & Growth Officer. “OverTier has a proven track record of innovation in Europe, and we look forward to unlocking significant potential across other markets.”
“We are delighted with the progress we’ve made with our NFL partners. Together we have built a detailed understanding of how to cultivate and super serve fans throughout Europe and have turned that into meaningful business gain with great long-term potential,” said Sam Jones, OverTier CEO. “We look forward to applying our unique model to these expanded global markets and with the league develop more fans and opportunities worldwide.”
Over the past two seasons, a suite of user-led product innovations delivered a more personalized viewing experience to more fans across more platforms and services in Europe than ever. There has been a meaningful growth in subscriptions to NFL Game Pass in Europe, total NFL GPE regular-season viewership was up 46% year-on-year (’17-’18), with average minutes per viewer increasing by 20% to 62 hours. Live Super Bowl viewership was up 33% year-on-year and playoff viewership up 30%. Mobile viewership increased by 26% year-on-year, while the total number of devices subscribers used to watch GPE increased by 33% (a GPE subscription allows up to five concurrent streams). Eight hundred million hours of content was streamed, representing over 91,000 years of content. The Android app was the highest rated of all sports subscription OTT services globally.
OverTier was created by Bruin to build and operate next-generation, sports, and entertainment direct-to-consumer streaming services. Bruin company, Deltatre, the global leader in sports media technology, provides the streaming platform technology. All marketing for OverTier on behalf of NFL Game Pass is led by Two Circles, a data-driven sports agency, with the support of Wavemaker, a full-service global media agency, both part of WPP’s GroupM.
Among the innovations to be rolled out in 2019 are:
- Watch Around The World: NFL Game Pass subscribers will be able to use their subscription in any of the 181 territories it is active
- Watch with RedZone: Thanks to new split-screen functionality, Season Pro subscribers will be able to watch NFL RedZone alongside one live game (outside of Europe).
- Smart TV and PS4 apps: NFL Game Pass is accessible on more devices, including Samsung and LG Smart TVs
- Film Sessions - Season 2: Across the 2019 season, 17 new installments of the hit series NFL Game Pass: Film Sessions will be available exclusively to NFL Game Pass International subscribers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005597/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom